Shots:

• Mylan signed an agreement to acquire the related IP and commercialization rights of Aspen’s thrombosis business in the EU for $758.59M which include ~$311.08M as up front and ~$447.46 as deferred payment
• The acquired portfolio includes Arixtra- Fraxiparine- Mono-Embolex- and Orgaran which complements and bolster Mylan's complex injectables offering and presence in hospitals
• The transaction is expected to be immediately accretive to Mylan upon closing and is anticipated to be accretive to VIATRIS upon the completion of Mylan's combination with Upjohn- anticipated to be close in Q4’20

 Ref: PRNewswire | Image: Worldkings